Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Public ClinicalTrials.gov record NCT06851858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Study identification
- NCT ID
- NCT06851858
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2025 (Actual)
- Primary completion
- May 26, 2026 (Actual)
- Completion
- May 26, 2026 (Actual)
- Last update posted
- Sep 24, 2026
2025 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35205 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Doral | Florida | 33166 | — |
| Research Site | Jacksonville | Florida | 32216 | — |
| Research Site | Miami | Florida | 33135 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Winter Park | Florida | 32789 | — |
| Research Site | Canton | Georgia | 30114 | — |
| Research Site | Fayetteville | Georgia | 30214 | — |
| Research Site | Chicago | Illinois | 60640 | — |
| Research Site | Oak Brook | Illinois | 60523 | — |
| Research Site | Newton | Kansas | 67114 | — |
| Research Site | Lexington | Kentucky | 40509 | — |
| Research Site | Kansas City | Missouri | 64114 | — |
| Research Site | Las Vegas | Nevada | 89119 | — |
| Research Site | Norman | Oklahoma | 73069 | — |
| Research Site | Knoxville | Tennessee | 37909 | — |
| Research Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06851858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06851858 live on ClinicalTrials.gov.